Off-label use of long-acting injectable antiretroviral therapy: A Single Center Retrospective Review of Youth Living with HIV with detectable HIV RNA starting Injectable Therapy

Alison Rousseau; Eric McGrath; Laura Benjamins; Salome Cockern; Jill Meade; Keshaum Houston; Melina Breaux; Elizabeth Secord

doi:10.1093/jpids/piae033

Off-label use of long-acting injectable antiretroviral therapy: A Single Center Retrospective Review of Youth Living with HIV with detectable HIV RNA starting Injectable Therapy

J Pediatric Infect Dis Soc. 2024 Apr 9:piae033. doi: 10.1093/jpids/piae033. Online ahead of print.

Authors

Alison Rousseau¹, Eric McGrath², Laura Benjamins³, Salome Cockern⁴, Jill Meade⁴, Keshaum Houston⁵, Melina Breaux⁵, Elizabeth Secord⁶

Affiliations

¹ Wayne State University School of Medicine (WSUSOM), Detroit MI, USA.
² Professor of Pediatrics, WSUSOM Division of Pediatric Infectious Disease, Detroit, MI, USA.
³ Professor of Pediatrics, WSUSOM, Division of Adolescent Medicine, Detroit, MI, USA.
⁴ Assistant Professor of Pediatrics, WSUSOM, Detroit, MI, USA.
⁵ WSUSOM, Detroit, MI, USA.
⁶ Professor of Pediatrics, WSUSOM, Division Chief for Allergy and Immunology, Detroit Michigan, USA.

PMID: 38591356
DOI: 10.1093/jpids/piae033

Abstract

Nineteen youth living with HIV (YLWH) opted for injectable cabotegravir and rilpivirine without oral lead in and without achieving an undetectable HIV viral load (VL) for the 3 months prior to initiation. All achieved undetectable status within 3 months (3 injections) and maintained an undetectable status through 6-12 months of therapy.

Keywords: Adherence; HIV; HIV+ youth; Injectable antiretrovirals; Perinatal.

© The Author(s) 2024. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.